Topics:

Survival After First Recurrence Has Improved Over 25 Years

Survival After First Recurrence Has Improved Over 25 Years

ORLANDO—A large review of patients treated at M.D. Anderson Cancer Center
suggests that survival after a first breast cancer recurrence has greatly
improved over time in patients diagnosed in the last 25 years. The
investigators believe that new therapies, above and beyond the anthracyclines,
may be affecting survival rates.

Consecutive series of adjuvant therapy studies from M.D. Anderson have
previously shown that anthracycline-based regimens decrease breast cancer
recurrence and death. Since the emergence of anthracyclines, multiple new
treatment modalities, including new hormonal, biologic, and cytotoxic agents,
have been developed, but their effect on survival has been unclear.

This study analyzed patients who were treated in consecutive series of
anthracycline-based adjuvant therapy protocols to determine if survival from
time of first recurrence improved between 1974 and 2000.

"These patients were uniformly treated and followed at a single
institution, and so provide a unique opportunity to evaluate possible changes
in survival over time," said Sharon Giordano, MD, assistant professor,
M.D. Anderson Cancer Center, who presented the study at a poster session of the
38th Annual Meeting of the American Society of Clinical Oncology (abstract
212).

A total of 1,986 patients were treated on five consecutive anthracycline-based
adjuvant therapy regimens from 1974 to 1994. The 842 patients who developed
recurrent disease were divided into five groups based on year of first
recurrence. Median and 3- and 5-year overall survival rates from time of first
recurrence were compared among the groups.

Differences among the groups were clearly evident in terms of survival, as
shown in the Table below. By log rank analysis, there was a highly statistically
significant improvement in survival from time of first recurrence across the
five groups (P < .001). The results were consistent across all the tumor stages, and
improved progressively with each 5-year treatment period, Dr. Giordano
reported.

The patient characteristics upon initial diagnosis changed somewhat over
time, shifting toward more stage I patients in recent years and fewer advanced
stage patients at diagnosis, Dr. Giordano said. Thus, the improvement in
survival could have been confounded by the unequal distribution of this
prognostic factor. However, she said, when the data were stratified by initial
stage, the finding of improved survival was still present. "These
differences were not factors in survival, which was evaluated from first
recurrence and not linked to initial disease factors," she commented.

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.